Mineralys Therapeutics (NASDAQ:MLYS) Announces Earnings Results

Mineralys Therapeutics (NASDAQ:MLYS) announced its earnings results on Wednesday. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02, Zacks reports.

Mineralys Therapeutics Trading Up 4.6 %

Mineralys Therapeutics stock traded up $0.45 on Wednesday, reaching $10.11. 67,507 shares of the stock were exchanged, compared to its average volume of 256,210. The firm has a fifty day moving average price of $11.31 and a two-hundred day moving average price of $12.06. Mineralys Therapeutics has a twelve month low of $8.58 and a twelve month high of $16.91. The stock has a market cap of $503.12 million, a PE ratio of -3.06 and a beta of 1.44.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research report on Tuesday, November 12th.

Insider Activity

In related news, CFO Adam Scott Levy sold 10,757 shares of the business’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total value of $97,888.70. Following the sale, the chief financial officer now owns 226,097 shares of the company’s stock, valued at $2,057,482.70. The trade was a 4.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jon Congleton sold 18,333 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $9.06, for a total transaction of $166,096.98. Following the sale, the chief executive officer now directly owns 877,608 shares in the company, valued at $7,951,128.48. This represents a 2.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 33.24% of the stock is owned by company insiders.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.